AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34853187 — intervention group
Group type: EXPERIMENTAL
Intervention: Uphill running (UR: 15%)
Number of subjects: 8
Study 33434227 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 104
Study 33434227 — intervention group
Group type: EXPERIMENTAL
Intervention: Focused attention (FA)
Number of subjects: 104
Study 33434227 — intervention group
Group type: EXPERIMENTAL
Intervention: Open monitoring (OM)
Number of subjects: 104
Study 35999431 — intervention group
Group type: EXPERIMENTAL
Intervention: Otago Exercise Program (OEP)
Number of subjects: 255
Study 35999431 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 255
Study 35778465 — intervention group
Group type: EXPERIMENTAL
Intervention: High-definition tDCS (HD-tDCS) at 1 mA to S1
Number of subjects: 45
Study 32873669 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 supplementation
Number of subjects: 0
Study 35260459 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical mobilisations targeting the painful and/or restricted cervical segments and a distraction manipulation of the cervicothoracic junction (N=75)
Number of subjects: 100
Study 35260459 — intervention group
Group type: COMPARATOR
Intervention: Placebo mobilisation and placebo manipulation (N=25)
Number of subjects: 100
Study 33860313 — intervention group
Group type: EXPERIMENTAL
Intervention: Follitropin alfa (GONAL-f; Merck KGaA)
Number of subjects: 8085
Study 34001059 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX plus regorafenib
Number of subjects: 69
Study 34001059 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFIRINOX (oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, irinotecan 150–180 mg/m2, 5‐fluorouracil: 400 mg/m2 then 2400 mg/m2 over 46 h) every 14 days with regorafenib (80 to 160 mg, orally, once daily on days 4 to 10 of each cycle)
Number of subjects: 69
Study 33498539 — intervention group
Group type: EXPERIMENTAL
Intervention: Mind Maps
Number of subjects: 45
Study 35104832 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fidelity Patient Simulation (HFPS)
Number of subjects: 82
Study 35104832 — intervention group
Group type: COMPARATOR
Intervention: Flipped Classroom (FC)
Number of subjects: 82
Study 32746455 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 hospitalization
Number of subjects: 1877
Study 32746455 — intervention group
Group type: COMPARATOR
Intervention: Medical admission (2019)
Number of subjects: 1877
Study 32746455 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 hospitalization vs. Medical admission (2019)
Number of subjects: 1877
Study 35714891 — intervention group
Group type: EXPERIMENTAL
Intervention: VascQOL
Number of subjects: 1830
Study 35714891 — intervention group
Group type: EXPERIMENTAL
Intervention: EQ5D
Number of subjects: 1830
Study 35714891 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-12
Number of subjects: 1830
Study 32927858 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual therapy + Exercise
Number of subjects: 58
Study 32927858 — intervention group
Group type: COMPARATOR
Intervention: Exercise
Number of subjects: 58
Study 35129113 — intervention group
Group type: EXPERIMENTAL
Intervention: Endometrial scratch
Number of subjects: 1048
Study 35129113 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 1048
Study 35339280 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranilast (300 mg daily) for 7 days
Number of subjects: 72
Study 35339280 — intervention group
Group type: COMPARATOR
Intervention: Control group (antiviral therapy only)
Number of subjects: 72
Study 33755924 — intervention group
Group type: EXPERIMENTAL
Intervention: Vafidemstat
Number of subjects: 110
Study 33755924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 32644875 — intervention group
Group type: EXPERIMENTAL
Intervention: Estradiol (E2) dose
Number of subjects: 1513
Study 32644875 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum E2 levels
Number of subjects: 1513
Study 34882632 — intervention group
Group type: EXPERIMENTAL
Intervention: Changing surgical instruments before wound closure (Group A)
Number of subjects: 453
Study 34882632 — intervention group
Group type: COMPARATOR
Intervention: Conventional closure (Group B)
Number of subjects: 453
Study 32988567 — intervention group
Group type: EXPERIMENTAL
Intervention: Twin-block (TB)
Number of subjects: 60
Study 32988567 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono-block (MB)
Number of subjects: 60
Study 32988567 — intervention group
Group type: EXPERIMENTAL
Intervention: Herbst (H)
Number of subjects: 60
Study 35107058 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined aerobic and resistance moderate intensity continuous training (C-MICT)
Number of subjects: 12
Study 35107058 — intervention group
Group type: COMPARATOR
Intervention: Combined aerobic and resistance high-intensity interval training (C-HIIT)
Number of subjects: 12
Study 35107058 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 12
Study 34161565 — intervention group
Group type: EXPERIMENTAL
Intervention: Let's Talk About Pain training
Number of subjects: 158
Study 34161565 — intervention group
Group type: COMPARATOR
Intervention: Control training
Number of subjects: 158
Study 34269885 — intervention group
Group type: EXPERIMENTAL
Intervention: LED
Number of subjects: 90
Study 34269885 — intervention group
Group type: EXPERIMENTAL
Intervention: CP
Number of subjects: 90
Study 34269885 — intervention group
Group type: EXPERIMENTAL
Intervention: LED/CP
Number of subjects: 90
Study 34269885 — intervention group
Group type: EXPERIMENTAL
Intervention: HP
Number of subjects: 90
Study 34269885 — intervention group
Group type: EXPERIMENTAL
Intervention: LED/HP
Number of subjects: 90
Study 34778144 — intervention group
Group type: EXPERIMENTAL
Intervention: Promelaxin microenemas
Number of subjects: 153
Study 34778144 — intervention group
Group type: COMPARATOR
Intervention: PEG 4000
Number of subjects: 153
Study 34087115 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 931
Study 34087115 — intervention group
Group type: COMPARATOR
Intervention: Sorafenib
Number of subjects: 931
Study 34468414 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity isometric exercise
Number of subjects: 48
Study 34468414 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity isometric exercise
Number of subjects: 48
Study 34468414 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 48
Study 32553417 — intervention group
Group type: EXPERIMENTAL
Intervention: GentleWave System (GWS)
Number of subjects: 0
Study 32553417 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment with conventional side-vented needle irrigation and ultrasonic activation (Control)
Number of subjects: 0
Study 32553417 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GWS and Control)
Number of subjects: 0
Study 34872102 — intervention group
Group type: EXPERIMENTAL
Intervention: Peripheral low‐concentration (10 µg/mL) norepinephrine infusion
Number of subjects: 60
Study 34872102 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%) infusion
Number of subjects: 60
Study 36037679 — intervention group
Group type: EXPERIMENTAL
Intervention: Milvexian (oral small-molecule inhibitor of FXIa)
Number of subjects: 2366
Study 36037679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2366
Study 33607802 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide
Number of subjects: 100
Study 33607802 — intervention group
Group type: COMPARATOR
Intervention: Torasemide
Number of subjects: 100
Study 32749411 — intervention group
Group type: EXPERIMENTAL
Intervention: i-C3H7O radicals dissociated at 248 nm
Number of subjects: 0
Study 32749411 — intervention group
Group type: EXPERIMENTAL
Intervention: i-C3H7O undergoing three-body fragmentation
Number of subjects: 0
Study 36067616 — intervention group
Group type: EXPERIMENTAL
Intervention: R + L (ribociclib plus letrozole)
Number of subjects: 106
Study 36067616 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 106
Study 34671228 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 100
Study 34671228 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 100
Study 36707979 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT + ABM
Number of subjects: 23
Study 36707979 — intervention group
Group type: COMPARATOR
Intervention: CBT + PBO
Number of subjects: 23
Study 33512079 — intervention group
Group type: EXPERIMENTAL
Intervention: High CRP levels
Number of subjects: 337
Study 33512079 — intervention group
Group type: EXPERIMENTAL
Intervention: Low CRP levels
Number of subjects: 337
Study 33512079 — intervention group
Group type: COMPARATOR
Intervention: Control group (no lab tests provided)
Number of subjects: 337
Study 32521891 — intervention group
Group type: EXPERIMENTAL
Intervention: TACE + 125I + 3DCRT
Number of subjects: 110
Study 32521891 — intervention group
Group type: COMPARATOR
Intervention: TACE + 3DCRT
Number of subjects: 110
Study 33358206 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser therapy
Number of subjects: 18
Study 33358206 — intervention group
Group type: COMPARATOR
Intervention: Sham laser treatment
Number of subjects: 18
Study 32447436 — intervention group
Group type: EXPERIMENTAL
Intervention: Information from articles
Number of subjects: 13
Study 32447436 — intervention group
Group type: COMPARATOR
Intervention: Additional sources of information
Number of subjects: 13
Study 35692220 — intervention group
Group type: EXPERIMENTAL
Intervention: Favipiravir + camostat + ciclesonide combination therapy
Number of subjects: 121
Study 35692220 — intervention group
Group type: COMPARATOR
Intervention: Favipiravir monotherapy
Number of subjects: 121
Study 36068002 — intervention group
Group type: EXPERIMENTAL
Intervention: Intralesional collagenase Clostridium histolyticum (CCH)
Number of subjects: 50
Study 36068002 — intervention group
Group type: COMPARATOR
Intervention: Intralesional verapamil (ILV)
Number of subjects: 50
Study 36068002 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient satisfaction
Number of subjects: 50
Study 33762129 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine
Number of subjects: 60
Study 33762129 — intervention group
Group type: COMPARATOR
Intervention: tACS
Number of subjects: 60
Study 34321055 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised text message (including recipient's name)
Number of subjects: 618
Study 34321055 — intervention group
Group type: COMPARATOR
Intervention: Standard text message
Number of subjects: 618
Study 34321055 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalised text message
Number of subjects: 618
Study 616354713 — intervention group
Group type: EXPERIMENTAL
Intervention: Helmet therapy
Number of subjects: 31
Study 616354713 — intervention group
Group type: COMPARATOR
Intervention: Postural correction training
Number of subjects: 31
Study 35652769 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mL 70% alcohol (CPN20 group)
Number of subjects: 32
Study 35652769 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mL 70% alcohol (CPN40 group)
Number of subjects: 32
Study 34070257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 1 (IG-1, n = 26) - received resistance and balance training three days a week in addition to usual inpatient CR program
Number of subjects: 63
Study 34070257 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention 2 (IG-2, n = 18) - received different resistance and balance training three days a week in addition to usual inpatient CR program
Number of subjects: 63
Study 34070257 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG, n = 19) - attended usual inpatient CR program
Number of subjects: 63
Study 32951335 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercises (RE group)
Number of subjects: 20
Study 32951335 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance exercises with whole‐body vibration (VRE group)
Number of subjects: 20
Study 32951335 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined resistance exercise intervention (TR group)
Number of subjects: 20
Study 32951335 — intervention group
Group type: COMPARATOR
Intervention: Nonexercise control (CTR group)
Number of subjects: 20
Study 33982890 — intervention group
Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 28
Study 33982890 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 28
Study 33982890 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined connectivity patterns (posterior cingulate and dorsolateral prefrontal cortex)
Number of subjects: 28
Study 33982890 — intervention group
Group type: COMPARATOR
Intervention: Functional connectivity patterns
Number of subjects: 28
Study 35272401 — intervention group
Group type: EXPERIMENTAL
Intervention: Fanzhen Jieci (warming acupuncture plus fast needling)
Number of subjects: 76
Study 35272401 — intervention group
Group type: COMPARATOR
Intervention: Conventional acupuncture
Number of subjects: 76
Study 34411523 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Management Support System - Primary Care (PMSS-PC) with education
Number of subjects: 528
Study 34411523 — intervention group
Group type: COMPARATOR
Intervention: Delayed implementation (control group)
Number of subjects: 528
Study 36121697 — intervention group
Group type: EXPERIMENTAL
Intervention: EMPOWER Electronic Delivery (EMPOWER‐ED)
Number of subjects: 23
Study 36121697 — intervention group
Group type: COMPARATOR
Intervention: Feedback from policy leaders
Number of subjects: 23
Study 32673267 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual clinical care + Mandolean training to reduce the rate of eating
Number of subjects: 20
Study 32673267 — intervention group
Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 20
Study 35427471 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg every 3 weeks
Number of subjects: 307
Study 35427471 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (mFOLFOX6 or FOLFIRI with or without bevacizumab or cetuximab)
Number of subjects: 307
Study 33135577 — intervention group
Group type: COMPARATOR
Intervention: 80% RM
Number of subjects: 11
Study 33135577 — intervention group
Group type: COMPARATOR
Intervention: Optimal Load
Number of subjects: 11
Study 32824771 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Flow Oxygen through Nasal Cannula (HFNC)
Number of subjects: 40
Study 32824771 — intervention group
Group type: COMPARATOR
Intervention: Non-Invasive Ventilation (NIV)
Number of subjects: 40
Study 34166195 — intervention group
Group type: EXPERIMENTAL
Intervention: Ankle dorsiflexion using a pressure‐activated pedal switch connected to web games
Number of subjects: 48
Study 34166195 — intervention group
Group type: COMPARATOR
Intervention: Ankle dorsiflexion exercises using a pedal switch that operated a home appliance (a fan)
Number of subjects: 48
Study 32671687 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG level 1 (≤ 5.6 mmol/L)
Number of subjects: 863
Study 32671687 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG level 2 (> 5.6 to ≤ 6.1 mmol/L)
Number of subjects: 863
Study 32671687 — intervention group
Group type: COMPARATOR
Intervention: FPG level 3 (> 6.1 to ≤ 7.0 mmol/L)
Number of subjects: 863
Study 32671687 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG level 1
Number of subjects: 863
Study 32671687 — intervention group
Group type: EXPERIMENTAL
Intervention: FPG level 2
Number of subjects: 863
Study 32671687 — intervention group
Group type: COMPARATOR
Intervention: FPG level 3
Number of subjects: 863
Study 35672003 — intervention group
Group type: EXPERIMENTAL
Intervention: KARLOTTA app used by 14 patients
Number of subjects: 30
Study 35672003 — intervention group
Group type: COMPARATOR
Intervention: Control group (15 patients)
Number of subjects: 30
Study 35672003 — intervention group
Group type: EXPERIMENTAL
Intervention: KARLOTTA app usage
Number of subjects: 30
Study 35672003 — intervention group
Group type: EXPERIMENTAL
Intervention: KARLOTTA app usability
Number of subjects: 30
Study 35672003 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life assessment
Number of subjects: 30
Study 33551193 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual distraction (cartoons)
Number of subjects: 120
Study 33551193 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory distraction (melodic poems)
Number of subjects: 120
Study 33551193 — intervention group
Group type: COMPARATOR
Intervention: Control group (no distraction)
Number of subjects: 120
Study 32459666 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-measured office BP (SMOBP)
Number of subjects: 200
Study 32459666 — intervention group
Group type: COMPARATOR
Intervention: Nurse-measured office BP (NMOBP)
Number of subjects: 200
Study 32459666 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in BP from first to third recording
Number of subjects: 200
Study 36102582 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided anterior quadratus lumborum block at the lateral supra-arcuate ligament (LAL-QLB)
Number of subjects: 74
Study 36102582 — intervention group
Group type: COMPARATOR
Intervention: Thoracic epidural analgesia (TEA)
Number of subjects: 74
Study 36102582 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL-QLB
Number of subjects: 74
Study 36102582 — intervention group
Group type: COMPARATOR
Intervention: TEA
Number of subjects: 74
Study 36102582 — intervention group
Group type: EXPERIMENTAL
Intervention: LAL-QLB and TEA
Number of subjects: 74
Study 33597289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab 10 mg/kg, 3 mg/kg, 1 mg/kg administered as IV infusions every 4 weeks
Number of subjects: 211
Study 33597289 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered as IV infusions every 4 weeks
Number of subjects: 211
Study 33597289 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimagrumab (all doses pooled)
Number of subjects: 211
Study 33597289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 35583581 — intervention group
Group type: EXPERIMENTAL
Intervention: Wen-Luo-Tong Granules (WLT) plus oral Mecobalamin for 1 week
Number of subjects: 78
Study 33979535 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise (five sessions each week for 4 weeks)
Number of subjects: 80
Study 33979535 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment only
Number of subjects: 80
Study 33727797 — intervention group
Group type: EXPERIMENTAL
Intervention: Test formulation of montelukast sodium chewable tablets
Number of subjects: 36
Study 33727797 — intervention group
Group type: COMPARATOR
Intervention: Reference formulation of montelukast sodium chewable tablets
Number of subjects: 36
Study 33727797 — intervention group
Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 36
Study 32334475 — intervention group
Group type: EXPERIMENTAL
Intervention: Holistic nursing intervention
Number of subjects: 204
Study 32334475 — intervention group
Group type: COMPARATOR
Intervention: Routine care (comparison group)
Number of subjects: 204
Study 34500109 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the primary motor cortex (M1)
Number of subjects: 39
Study 34500109 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS of the dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 39
Study 34500109 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent anodal tDCS over M1 and DLPFC
Number of subjects: 39
Study 34500109 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 39
Study 33902546 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive augmented reality-based telerehabilitation in conjunction with hospital-based physical therapy for 3 months
Number of subjects: 100
Study 33902546 — intervention group
Group type: COMPARATOR
Intervention: Usual care (hospital-based physical therapy in conjunction with a home-based exercise described in a brochure) for 3 months
Number of subjects: 100
Study 33902546 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive augmented reality-based telerehabilitation
Number of subjects: 100
Study 33902546 — intervention group
Group type: COMPARATOR
Intervention: Usual care (hospital-based physical therapy in conjunction with a home-based exercise described in a brochure)
Number of subjects: 100
Study 36460017 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (840 mg intravenously on day 1 and 15) plus vemurafenib (960 mg or 720 mg twice daily orally) and cobimetinib (60 mg once daily orally; 21 days on and 7 days off)
Number of subjects: 514
Study 36460017 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus vemurafenib (960 mg or 720 mg twice daily orally) and cobimetinib (60 mg once daily orally; 21 days on and 7 days off)
Number of subjects: 514
Study 36460017 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab (840 mg intravenously on day 1 and 15) plus vemurafenib and cobimetinib
Number of subjects: 514
Study 36460017 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus vemurafenib and cobimetinib
Number of subjects: 514
Study 33106326 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 0
Study 32676959 — intervention group
Group type: EXPERIMENTAL
Intervention: Extrapleural autologous blood injection (EPABI) + Intraparenchymal autologous blood patch injection (IABPI), n = 40
Number of subjects: 81
Study 32676959 — intervention group
Group type: COMPARATOR
Intervention: Intraparenchymal autologous blood patch injection (IABPI) only, n = 41
Number of subjects: 81
Study 32676959 — intervention group
Group type: COMPARATOR
Intervention: Control group (IABPI only)
Number of subjects: 81
Study 32676959 — intervention group
Group type: EXPERIMENTAL
Intervention: Study group (EPABI + IABPI)
Number of subjects: 81
Study 35554617 — intervention group
Group type: EXPERIMENTAL
Intervention: high/fast: 1.0 mg nicotine delivered over 5 pulsed-infusions, then 15 saline infusions
Number of subjects: 12
Study 35554617 — intervention group
Group type: EXPERIMENTAL
Intervention: high/slow: 1.0 mg nicotine delivered over 20 pulsed-infusions
Number of subjects: 12
Study 35554617 — intervention group
Group type: EXPERIMENTAL
Intervention: low/fast: 0.2 mg nicotine delivered over 5 pulsed-infusions, then 15 saline infusions
Number of subjects: 12
Study 35554617 — intervention group
Group type: EXPERIMENTAL
Intervention: low/slow: 0.2 mg nicotine delivered over 20 pulsed-infusions
Number of subjects: 12
Study 35554617 — intervention group
Group type: COMPARATOR
Intervention: placebo: Saline delivered over 20 pulsed-infusions
Number of subjects: 12
Study 33021649 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer comparison emails (up to 3 emails over 6 months)
Number of subjects: 56